Skip to main content

Clinical Trials Using Hafnium Oxide-containing Nanoparticles NBTXR3

Review the clinical trials studying hafnium oxide-containing nanoparticles nbtxr3 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-7 of 7

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Status: Active
Location: 10 locations
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 7 locations
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
Status: Active
Location: 4 locations
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
NBTXR3, Radiation Therapy, and Immunotherapy (Anti-PD-1/L-1) for the Treatment of Lung and/or Liver or Soft Tissue Metastases from Solid Malignancy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas